7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 
      
    		                               
      cash flows from operating activities
    		                               
      net income
    		-15,737,000 -17,142,000 -18,892,000 -6,791,000 -19,170,000 -11,350,000 -13,109,000 -11,831,000 -16,923,000 -18,140,000 -14,791,000 -13,164,000 -20,276,000 -23,471,000 -17,501,000 -18,177,000 -19,433,000 -15,601,000 6,401,000 -110,694,000 -11,459,000 -21,125,000 -19,735,000 -14,508,000 -26,984,000 -37,567,000 -10,975,000 -12,442,000 -11,830,000 -16,433,000 -6,162,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                               
      depreciation and amortization
    		1,951,000 1,738,000 1,563,000 1,374,000 1,087,000 1,427,000 1,409,000 1,373,000 1,311,000 1,247,000 1,202,000 1,027,000 920,000 853,000 922,000 920,000 923,000 1,746,000 2,033,000 1,876,000 1,744,000 1,658,000 1,749,000 1,468,000 1,202,000 978,000 484,000 2,000 3,000   
      stock-based compensation
    		5,135,000 4,488,000 5,928,000 6,171,000 5,220,000 5,784,000 5,079,000 4,397,000 4,596,000 4,171,000 3,294,000 2,412,000 2,483,000 2,979,000 2,959,000 2,649,000 2,476,000 2,861,000 1,590,000 2,630,000 2,952,000 2,374,000 2,628,000 2,537,000 2,526,000 2,457,000 1,998,000 1,860,000 1,481,000 2,624,000 1,006,000 
      benefit from bad debts
    		2,210,000 703,000 1,051,000 790,000 889,000 582,000 188,000 86,000 1,012,000 69,000 273,000 235,000 624,000 274,000 465,000 88,000 188,000 -297,000 610,000 -373,000 -168,000 0 2,607,000         
      amortization of operating lease right-of-use assets
    		330,000 309,000 263,000 238,000 184,000 153,000 148,000 144,000 166,000 215,000 209,000 202,000 197,000 191,000 185,000 180,000 176,000 170,000 166,000 164,000 160,000 161,000 169,000 171,000 179,000 304,000 219,000     
      amortization of debt discount and issuance costs
    		336,000 309,000 301,000 298,000 290,000 282,000 277,000 273,000 266,000 279,000 298,000 281,000 272,000 270,000 263,000 59,000 302,000 294,000 286,000 698,000 703,000 643,000 647,000 643,000 624,000 608,000 281,000     
      deferred income taxes
    		-21,000 20,000 -5,000 -23,000 0 -3,000 5,000     -3,000 -4,000 6,000 -17,000     -154,000 -11,000 -66,000 256,000 -156,000 -149,000 -227,000 -14,523,000     
      revaluation of contingent royalty obligation payable to evolus founders
    		-107,000 -3,914,000 2,151,000  2,428,000 1,605,000 1,578,000  1,802,000 1,682,000 1,648,000  1,216,000 1,414,000 1,316,000  1,400,000 1,381,000 1,268,000  -2,471,000 2,433,000 -9,884,000  1,795,000       
      other adjustments to operating activities
    		251,000                               
      changes in operating assets and liabilities:
    		                               
      inventories
    		-11,492,000 -8,341,000 4,050,000 979,000 -1,476,000 -1,560,000 5,309,000 4,847,000 4,956,000 848,000 -6,458,000 4,595,000 -2,658,000 -7,054,000 -5,571,000 4,182,000 -7,181,000 -3,129,000 3,149,000 3,006,000 1,266,000 2,199,000 -1,929,000 1,743,000 5,297,000 -8,944,000 -2,578,000     
      accounts receivable
    		-4,936,000 -958,000 -823,000 -3,829,000 -2,383,000 -9,491,000 -3,899,000 -151,000 -2,480,000 -5,610,000 -1,280,000 -1,763,000 -518,000 -4,500,000 -2,608,000 -1,456,000 -1,613,000 -3,751,000 1,254,000 2,092,000 -2,582,000 1,757,000 -2,352,000 -3,842,000 -5,796,000       
      prepaid expenses
    		188,000 -1,340,000 -103,000 50,000 2,108,000 171,000 22,000 -2,045,000 642,000 -138,000 -257,000 -246,000 3,750,000 -2,873,000 549,000  1,253,000 -273,000 -636,000             
      accounts payable
    		4,112,000 -777,000 4,722,000 -2,889,000 3,526,000 -1,155,000 909,000 -5,806,000 1,364,000 283,000 3,142,000 -1,370,000 -2,056,000 2,923,000 1,471,000 1,525,000 -763,000 259,000 -1,808,000 5,165,000   332,000 -553,000   305,000 897,000 -93,000 266,000 205,000 
      accrued expenses
    		2,517,000 1,337,000 -14,172,000 5,877,000 2,160,000 7,851,000 -8,874,000 7,100,000 2,529,000 2,075,000 -2,685,000 -5,089,000 1,346,000 7,398,000 -8,854,000 6,557,000 -922,000 11,791,000 3,465,000 2,678,000   -3,949,000 -4,742,000   2,667,000 -1,092,000 1,890,000 574,000 1,361,000 
      operating lease liabilities
    		-290,000 -177,000 -79,000 -194,000 -169,000 -182,000 -171,000 -159,000 -198,000 -280,000 -270,000 -254,000 -248,000 -243,000 -232,000 -219,000 -213,000 -209,000 -197,000 -178,000 -174,000 -201,000 -181,000 -123,000 -122,000 -187,000 -222,000     
      other operating assets
    		884,000                               
      net cash from operating activities
    		-14,669,000 -24,791,000 -15,632,000 4,808,000 -5,722,000 -6,470,000 -10,615,000 813,000 -924,000 -13,310,000 -20,587,000 -8,774,000 -17,051,000 -20,888,000 -38,199,000 -9,044,000 -32,125,000 16,116,000 -8,335,000 -2,266,000 -13,713,000 -13,945,000 -27,947,000 -15,922,000 -25,103,000 -33,158,000 -19,200,000 -12,006,000 -5,797,000 -5,663,000 -2,201,000 
      capex
    		-955,000 -688,000 -319,000 -438,000 -313,000 -465,000 -256,000 -209,000 -29,000 -8,000 -227,000 -866,000 -509,000 -231,000 -12,000 0 0 0 0 -17,000 -121,000 -112,000 -565,000 1,000 0 0 0 0 0 0 0 
      free cash flows
    		-15,624,000 -25,479,000 -15,951,000 4,370,000 -6,035,000 -6,935,000 -10,871,000 604,000 -953,000 -13,318,000 -20,814,000 -9,640,000 -17,560,000 -21,119,000 -38,211,000 -9,044,000 -32,125,000 16,116,000 -8,335,000 -2,283,000 -13,834,000 -14,057,000 -28,512,000 -15,921,000 -25,103,000 -33,158,000 -19,200,000 -12,006,000 -5,797,000 -5,663,000 -2,201,000 
      cash flows from investing activities
    		                               
      purchases of property and equipment
    		-955,000 -688,000 -319,000 -438,000 -313,000 -465,000 -256,000 -209,000 -29,000 -8,000 -227,000 -866,000 -509,000 -231,000 -12,000     -17,000 -121,000 -112,000 -565,000 1,000 0   0 0   
      additions to capitalized software
    		-1,203,000 -1,579,000 -1,542,000 -924,000 -1,097,000 -789,000 -541,000 -152,000 -510,000 -208,000 -284,000 -525,000 -390,000 -157,000 -249,000 3,000 21,000 -386,000 -215,000 -282,000 -578,000 -528,000 -935,000 -1,142,000 -639,000 -1,618,000 -823,000     
      net cash from investing activities
    		-2,158,000 -2,267,000 -1,861,000 -1,362,000 -1,410,000 -1,254,000 -797,000 -361,000 -539,000 -216,000 -511,000 -1,391,000 -899,000 -388,000 -261,000 -390,000 21,000 -386,000 4,785,000 19,701,000 29,301,000 9,380,000 -46,188,000 13,974,000 34,390,000 8,227,000 -80,025,000 0 0   
      cash flows from financing activities
    		                               
      payment of contingent royalty obligation to evolus founders
    		-1,786,000 -2,051,000 -2,365,000 -1,829,000 -2,005,000 -1,778,000 -1,829,000 -1,499,000 -1,479,000 -1,251,000 -1,308,000 -1,016,000 -1,114,000 -1,016,000 -1,039,000 -802,000 -783,000 -983,000 -529,000 0 -233,000 -315,000 -583,000 -395,000 -69,000       
      proceeds from issuance and modification of debt instruments
    		0                               
      payments for debt modification fees and costs
    		0                               
      proceeds from follow-on offering
    		                               
      payments for offering costs
    		   0 0           0 0           0 -300,000 -74,000 -686,000 
      issuance of common stock in connection with incentive equity plan
    		18,000 323,000 742,000  589,000 2,300,000 487,000 29,000 60,000 109,000 26,000 0 355,000 167,000 17,000 1,000 -1,000 644,000 11,000     1,346,000 314,000       
      payment of financing lease obligation
    		-4,000                               
      net cash from financing activities
    		-1,772,000 20,663,000 -1,631,000 -1,313,000 -1,416,000 4,481,000 45,662,000 23,522,000 -1,419,000 23,820,000 -1,282,000 -1,516,000 -759,000 -849,000 -1,022,000 47,894,000 8,163,000 93,836,000 -76,841,000 0 39,767,000 -315,000 -1,105,000 72,724,000 -460,000 853,000 60,430,000 0 67,380,000 -313,000 51,771,000 
      effect of exchange rates on cash and cash equivalents
    		384,000                               
      net increase in cash and cash equivalents
    		-18,215,000                               
      cash and cash equivalents, beginning of period
    		0 0 86,952,000 0 0 0 62,838,000 0 0 0 53,922,000 0 0 0 146,256,000 0 0 0 102,562,000 0 0 0 109,892,000 0 0 0 93,162,000     
      cash and cash equivalents, end of period
    		-18,215,000 -6,156,000 67,894,000 1,917,000 -8,636,000 -3,287,000 96,958,000 24,153,000 -3,020,000 10,242,000 31,463,000 -11,650,000 -18,912,000 -22,187,000 106,671,000 38,460,000 -23,941,000 109,566,000 22,171,000 17,435,000 55,355,000 -4,880,000 34,652,000 70,776,000 8,827,000 -24,078,000 54,367,000     
      other
    		  146,000                             
      changes in assets and liabilities:
    		                               
      other assets
    		  -1,733,000 1,192,000 -416,000 -584,000 514,000 -974,000 33,000 -11,000 88,000  -2,099,000 945,000 3,454,000   -4,626,000 -1,657,000 201,000 1,105,000 98,000 93,000         
      proceeds from follow-on offering, net of underwriters fees
    		    0 4,207,000 47,004,000          0               
      tax withholding paid on behalf of employees for stock-based awards
    		  -8,000                        -58,000     
      effect of exchange rates on cash
    		  66,000  -88,000 -44,000 -130,000 179,000 -138,000 -52,000 -79,000 31,000 -203,000 -62,000 -103,000                 
      change in cash and cash equivalents
    		  -19,058,000 1,917,000 -8,636,000 -3,287,000 34,120,000 24,153,000 -3,020,000 10,242,000 -22,459,000 -11,650,000 -18,912,000 -22,187,000 -39,585,000 38,460,000 -23,941,000 109,566,000 -80,391,000 17,435,000 55,355,000 -4,880,000 -75,240,000 70,776,000 8,827,000 -24,078,000 -38,795,000     
      revaluation of contingent royalty obligation to evolus founders
    		                               
      non-cash in-process research and development expense
    		                               
      accrued litigation settlement
    		       0 0 0 -5,000,000 0 0 0 -15,000,000 0                
      proceeds from issuance of long-term debt, net of discounts
    		       25,000,000 0               0 0 0 73,906,000     
      payments for debt issuance costs
    		       -8,000 0               0 0 0 -2,205,000     
      proceeds from follow-on offering, net of underwriting fees
    		                               
      cash proceeds from exercise of stock options
    		                               
      tax withholding paid on behalf of employees for net share settlement
    		                               
      amortization of discount on short-term investments
    		                   -7,000 -30,000 -221,000 -169,000   -466,000 -120,000     
      income from extinguishment of debts
    		               0 0 0 968,000             
      other current assets
    		                               
      maturities of short-term investments
    		               0 0 0 5,000,000 20,000,000 30,000,000 35,000,000 5,000,000 30,000,000 40,000,000       
      repayment of long term debt
    		               0 0 0 -76,323,000             
      repayment of promissory note payable to evolus founders
    		                               
      proceeds from atm sales of shares
    		               0 8,947,000               
      paid-in-kind interest on convertible note
    		                -1,000 0 273,000 303,000            
      consideration receivable from daewoong
    		                  -25,500,000             
      non-cash portion of accrued settlement expenses
    		                               
      prepaid expenses and other current assets
    		                   -1,009,000 -1,755,000 -697,000 1,771,000 -468,000 591,000 -348,000 -1,649,000 -253,000 115,000 -498,000 -356,000 
      purchases of short-term investments
    		                   0 0 -24,980,000 -49,688,000 -14,885,000 -4,971,000 -14,809,000 -79,202,000     
      proceeds from issuance of convertible note
    		                   0            
      payment for debt obligation
    		                   0 0 0 -522,000 -339,000        
      accrued settlement expenses
    		                               
      milestone payment for intangible assets
    		                       -1,000,000 0 0 -2,000,000     
      proceeds from issuance of term loan, net of discounts
    		                               
      accounts payable and accrued expenses
    		                               
      provisions for rebate and coupon programs
    		                       5,654,000        
      deferred rent
    		                           -5,000 -3,000 -3,000 -2,000 
      proceeds from initial public offering, net of underwriting fees
    		                               
      related party borrowings
    		                           0 0 0 1,127,000 
      payments on related party borrowings
    		                           0 0 0 -5,000,000 
      accretion of discount on short-term investments
    		                               
      proceeds from initial public offering, net of underwriters fees
    		                            0 0 56,330,000 
      revaluation of contingent royalty obligation payable to evolus founders, a related party
    		                          4,913,000  2,300,000   
      related party accounts payable
    		                              730,000 
      payment of contingent royalty obligation to evolus founders, a related party
    		                          -9,213,000     
      interest expense
    		                           114,000 321,000 321,000 107,000 
      tax benefit from therapeutic option right
    		                               
      revaluation of contingent royalty obligation to evolus founders, a related party
    		                               
      change in cash and restricted cash
    		                           -12,006,000 61,583,000   
      cash and restricted cash, beginning of period
    		                               
      cash, end of period
    		                           -12,006,000 61,583,000   
      supplemental disclosure of cash flow information
    		                               
      noncash financing activities:
    		                               
      related party receivable
    		                           0 0 0 73,690,000 
      note obligation
    		                           0 0 0 -140,688,000 
      contingent royalty obligation payable to evolus founders, a related party
    		                           0 0   
      contingent promissory note payable to evolus founders, a related party
    		                           0 0   
      capital contribution from parent, convertible note write-off
    		                           0 0 0 66,998,000 
      capital distribution to parent
    		                               
      capital contribution from parent, forgiveness of related party borrowings
    		                           0 0 0 13,188,000 
      capital contribution from parent - therapeutic option right, net of tax
    		                               
      deferred offering costs accrued, unpaid
    		                               
      deferred offering costs
    		                           0    
      accounts payable, paid by parent
    		                           0 0 0 -163,000 
      •
    		                               
      income tax expense
    		                            19,000 12,000 10,000 
      minimum tax withholding paid on behalf of employees for share-based awards
    		                            0   
      cash and restricted cash, beginning
    		                               
      non-cash financing activities:
    		                               
      capital distribution from parent
    		                               
      deferred ipo costs
    		                             0 -2,885,000 
      deferred offering costs, unpaid
    		                             52,000 -74,000 
      revaluation of contingent royalty obligation payable to related party
    		                              900,000 
      change in cash, cash equivalents, and restricted cash
    		                              49,570,000 
      cash, cash equivalents, and restricted cash, beginning
    		                               
      cash and cash equivalents, ending
    		                              49,570,000 
      contingent royalty obligation payable to related party
    		                              39,700,000 
      contingent promissory note payable to related party
    		                              16,042,000 
      adjustments to reconcile net income to net cash from operating activities
    		                               
      changes in assets and liabilities
    		                               
      release (payment) of restricted cash
    		                               
      deemed distribution
    		                               
      capital contribution - therapeutic option right, net of tax
    		                               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.